Salary, Integrity and Selection of a New Chair for California’s $12 Billion Cell and Gene Therapy Enterprise
By David Jensen,
The California Stem Cell Report
| 05. 20. 2022
Photo by Giorgio Trovato on Unsplash
The directors of the $12 billion California stem cell agency are looking for a new chair who is both decisive and collaborative, passionate and inclusive. But at the top of the wish list is a person who is a pillar of integrity.
At least that is what a survey of the 35 board members showed today. The results were released this afternoon, less than one business day before the directors’ Governance Subcommittee takes up the matter of compensation and qualifications for the new chair.
The post carries a salary range that currently tops out at $566,500 annually. But that could be boosted by the directors of the California Institute for Regenerative Medicine (CIRM), as the agency is officially known. Also figuring into the salary is whether the post should be a full-time job.
The new chair will oversee CIRM during the next decade or so, a period in which its results are likely to determine whether it lives or dies. Depending on its pace of spending, the agency will run out of cash...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...